Crossref
26-A-13603-ACC TIRZEPATIDE VERSUS GLP-1 RECEPTOR AGONISTS IN OBESE ADULTS WITHOUT DIABETES: REAL-WORLD CARDIOMETABOLIC OUTCOMES
JACC · 2026-04 · 87 (13) · A273
DOI: 10.1016/j.jacc.2026.02.678 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC, 2026-04. Verfasst von Abdul Rasheed Bahar und 4 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Bahar, A. R., Bahar, Y., Jawadi, M. H. H., Bolaji, O. A., & Afonso, L. C. (2026). 26-A-13603-ACC TIRZEPATIDE VERSUS GLP-1 RECEPTOR AGONISTS IN OBESE ADULTS WITHOUT DIABETES: REAL-WORLD CARDIOMETABOLIC OUTCOMES. JACC, 87(13), A273. https://doi.org/10.1016/j.jacc.2026.02.678
Vancouver
Bahar AR, Bahar Y, Jawadi MHH, Bolaji OA, Afonso LC. 26-A-13603-ACC TIRZEPATIDE VERSUS GLP-1 RECEPTOR AGONISTS IN OBESE ADULTS WITHOUT DIABETES: REAL-WORLD CARDIOMETABOLIC OUTCOMES. JACC. 2026;87(13):A273. doi:10.1016/j.jacc.2026.02.678
BibTeX
@article{Bahar2026,
author = {Bahar, Abdul Rasheed and Bahar, Yasemin and Jawadi, Mohamad Hasan Hasan and Bolaji, Olayiwola Akeem and Afonso, Luis C.},
title = {26-A-13603-ACC TIRZEPATIDE VERSUS GLP-1 RECEPTOR AGONISTS IN OBESE ADULTS WITHOUT DIABETES: REAL-WORLD CARDIOMETABOLIC OUTCOMES},
journal = {JACC},
year = {2026},
volume = {87},
number = {13},
pages = {A273},
doi = {10.1016/j.jacc.2026.02.678}
}
EUVIMED